Cargando…

Functional expression of Tim-3 on blasts and clinical impact of its ligand galectin-9 in myelodysplastic syndromes

T-cell immunoglobulin mucin-3 (Tim-3), an inhibitory immune checkpoint receptor, is highly expressed on acute myeloid leukemia cells and its ligand galectin-9 is reported to drive leukemic progression by binding with Tim-3. However, it remains unclear whether the Tim-3–galectin-9 pathway is associat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Asayama, Toshio, Tamura, Hideto, Ishibashi, Mariko, Kuribayashi-Hamada, Yasuko, Onodera-Kondo, Asaka, Okuyama, Namiko, Yamada, Akiko, Shimizu, Masumi, Moriya, Keiichi, Takahashi, Hidemi, Inokuchi, Koiti
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5687656/ https://www.ncbi.nlm.nih.gov/pubmed/29179486 http://dx.doi.org/10.18632/oncotarget.21492

Ejemplares similares

Clinical impact of serum soluble SLAMF7 in multiple myeloma
por: Ishibashi, Mariko, et al.
Publicado: (2018)

Immunotherapy for Multiple Myeloma
por: Tamura, Hideto, et al.
Publicado: (2019)

PD-L1–PD-1 Pathway in the Pathophysiology of Multiple Myeloma
por: Tamura, Hideto, et al.
Publicado: (2020)

A primary esophageal MALT lymphoma patient with Helicobacter pylori infection achieved complete remission after H. pylori eradication without anti-lymphoma treatment
por: Moriya, Keiichi, et al.
Publicado: (2016)

Induction of tumor-specific acquired immunity against already established tumors by selective stimulation of innate DEC-205(+) dendritic cells
por: Moriya, Keiichi, et al.
Publicado: (2010)

Tim3 binding to galectin-9 stimulates antimicrobial immunity
por: Jayaraman, Pushpa, et al.
Publicado: (2010)

TIM-3 Does Not Act as a Receptor for Galectin-9
por: Leitner, Judith, et al.
Publicado: (2013)

High Tim-3 expression on AML blasts could enhance chemotherapy sensitivity
por: Xu, Liangjing, et al.
Publicado: (2017)

Clinical efficacy of azacytidine and venetoclax and prognostic impact of Tim-3 and galectin-9 in acute myeloid leukemia and high-risk myelodysplastic syndromes: A single-center real-life experience
por: Giudice, Valentina, et al.
Publicado: (2022)

The Tim-3-Galectin-9 Pathway and Its Regulatory Mechanisms in Human Breast Cancer
por: Yasinska, Inna M., et al.
Publicado: (2019)

The immune receptor Tim-3 acts as a trafficker in a Tim-3/galectin-9 autocrine loop in human myeloid leukemia cells
por: Gonçalves Silva, Isabel, et al.
Publicado: (2016)

Involvement of Galectin-9/TIM-3 Pathway in the Systemic Inflammatory Response in Early-Onset Preeclampsia
por: Miko, Eva, et al.
Publicado: (2013)

Decreased Galectin-9 and Increased Tim-3 Expression Are Related to Poor Prognosis in Gastric Cancer
por: Jiang, Jing, et al.
Publicado: (2013)

Focal blast crisis in concomitant myelodysplastic syndrome and chronic myelogenous leukemia
por: Reap, Leo, et al.
Publicado: (2020)

Prognostic impact of immunophenotypic aberrancies of blasts in lower risk myelodysplastic syndrome
por: Corrao, Kristen, et al.
Publicado: (2022)

Upregulation of the Tim-3/Galectin-9 Pathway of T Cell Exhaustion in Chronic Hepatitis B Virus Infection
por: Nebbia, Gaia, et al.
Publicado: (2012)

Upregulated Tim-3/galectin-9 expressions in acute lung injury in a murine malarial model
por: Liu, Jinfeng, et al.
Publicado: (2015)

Peripheral Blood TIM-3 Positive NK and CD8+ T Cells throughout Pregnancy: TIM-3/Galectin-9 Interaction and Its Possible Role during Pregnancy
por: Meggyes, Matyas, et al.
Publicado: (2014)

Galectin-9/TIM-3 Interaction Regulates Virus-Specific Primary and Memory CD8(+) T Cell Response
por: Sehrawat, Sharvan, et al.
Publicado: (2010)

The Tim-3-galectin-9 Secretory Pathway is Involved in the Immune Escape of Human Acute Myeloid Leukemia Cells
por: Gonçalves Silva, Isabel, et al.
Publicado: (2017)

Circulating T Cells Exhibit Different TIM3/Galectin-9 Expression in Patients with Obesity and Obesity-Related Diabetes
por: Sun, Lili, et al.
Publicado: (2020)

Different Expression Pattern of TIM-3 and Galectin-9 Molecules by Peripheral and Peritoneal Lymphocytes in Women with and without Endometriosis
por: Meggyes, Matyas, et al.
Publicado: (2020)

Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy
por: Yang, Riyao, et al.
Publicado: (2021)

Galectin-9/Tim-3 pathway mediates dopaminergic neurodegeneration in MPTP-induced mouse model of Parkinson’s disease
por: Peng, Qinyu, et al.
Publicado: (2022)

The Variations’ in Genes Encoding TIM-3 and Its Ligand, Galectin-9, Influence on ccRCC Risk and Prognosis
por: Andrzejczak, Anna, et al.
Publicado: (2023)

Bullous Pemphigoid in an Elderly Patient with Myelodysplastic Syndrome and Refractory Anemia Coupled with Excess of Blast
por: Lee, Yin Yin, et al.
Publicado: (2011)

Tim-3-mediated signaling in NK cells may be modulated by increased Galectin-9 expression in HIV-1 infection
por: Jost, S, et al.
Publicado: (2012)

Dysregulated Tim-3 expression on natural killer cells is associated with increased Galectin-9 levels in HIV-1 infection
por: Jost, Stephanie, et al.
Publicado: (2013)

The immunologic advantage of recurrent nasopharyngeal carcinoma from the viewpoint of Galectin-9/Tim-3-related changes in the tumour microenvironment
por: Chen, Tseng-Cheng, et al.
Publicado: (2017)

High Expression of TIM 3 and Galectin 9 on Immunohistochemistry Staining of Tumor Specimen at Diagnosis in Pediatric Patients with Ewing Sarcoma
por: Si, Stephanie J., et al.
Publicado: (2021)

Proteome Changes in the Plasma of Myelodysplastic Syndrome Patients with Refractory Anemia with Excess Blasts Subtype 2
por: Majek, Pavel, et al.
Publicado: (2014)

Plasma protein alterations in the refractory anemia with excess blasts subtype 1 subgroup of myelodysplastic syndrome
por: Májek, Pavel, et al.
Publicado: (2012)

Correlation Between Bone Marrow Blasts Counts With Flow Cytometry and Morphological Analysis in Myelodysplastic Syndromes
por: Huang, Min, et al.
Publicado: (2017)

Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia
por: Kenealy, Melita, et al.
Publicado: (2019)

Pseudomonas aeruginosa ventriculitis following pancytopenia due to myelodysplastic syndrome with an excess of blasts type 2
por: Scorza, Carla Alexandra, et al.
Publicado: (2023)

SUV39H1-DNMT3A-mediated epigenetic regulation of Tim-3 and galectin-9 in the cervical cancer
por: Zhang, Li, et al.
Publicado: (2020)

Galectin-9/TIM-3 as a Key Regulator of Immune Response in Gliomas With Chromosome 1p/19q Codeletion
por: Li, Guanzhang, et al.
Publicado: (2021)

Mast cell activation is enhanced by Tim1:Tim4 interaction but not by Tim-1 antibodies
por: Phong, Binh, et al.
Publicado: (2016)

TIM-3 Expression Level on AML Blasts Correlates With Presence of Core Binding Factor Translocations Rather Than Clinical Outcomes
por: Hong, Jian, et al.
Publicado: (2022)

Lenalidomide Plus Decitabine Treatment in a Myelodysplastic Syndrome Patient With Deletion 5q and Excess Blasts
por: Serin, Istemi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ebvbalcrttknl1qqm2cktrqllh